Characteristics of patients, their donors, and transplantation, 2007 to 2011
| . | Donor age, years . | ||
|---|---|---|---|
| 18 to 32 . | 33 to 50 . | >50 . | |
| Number | 2614 | 1794 | 282 |
| Donor characteristics | |||
| Donor-recipient HLA-match | |||
| 8/8 matched | 2114 (81%) | 1326 (74%) | 181 (64%) |
| 7/8 matched | 500 (19%) | 468 (26%) | 101 (36%) |
| Donor-recipient ABO match | |||
| Matched | 874 (33%) | 563 (31%) | 79 (28%) |
| Minor mismatch | 453 (17%) | 374 (21%) | 53 (19%) |
| Major mismatch | 615 (24%) | 442 (25%) | 86 (30%) |
| Not reported | 672 (26%) | 415 (23%) | 64 (23%) |
| Donor sex and parity | |||
| Male | 1789 (68%) | 1218 (68%) | 153 (54%) |
| Female, nulliparous | 645 (25%) | 110 (6%) | 26 (9%) |
| Female, parity, 1 or more | 157 (6%) | 448 (25%) | 102 (36%) |
| Not reported | 23 (<1%) | 18 (1%) | 1 (<1%) |
| Donor-recipient cytomegalovirus serostatus | |||
| Donor and recipient negative | 772 (30%) | 504 (28%) | 57 (20%) |
| Donor negative, recipient positive | 992 (38%) | 580 (32%) | 94 (33%) |
| Donor and recipient positive | 229 (9%) | 229 (13%) | 38 (13%) |
| Donor positive, recipient positive | 598 (23%) | 461 (26%) | 86 (30%) |
| Not reported | 23 (< 1%) | 20 (1%) | 7 (2%) |
| Patient characteristics | |||
| Patient age, years | |||
| <18 | 304 (12%) | 198 (11%) | 22 (8%) |
| 18 to 45 | 938 (36%) | 605 (34%) | 101 (36%) |
| >45 | 1372 (52%) | 991 (55%) | 159 (56%) |
| Performance score | |||
| <90 | 822 (31%) | 589 (33%) | 86 (30%) |
| 90 or 100 | 1702 (65%) | 1124 (63%) | 190 (67%) |
| Not reported | 90 (3%) | 81 (5%) | 6 (2%) |
| Disease | |||
| Acute myeloid leukemia | 1630 (62%) | 1122 (63%) | 174 (62%) |
| Acute lymphoblastic leukemia | 593 (23%) | 406 (23%) | 66 (23%) |
| Chronic myeloid leukemia | 194 (7%) | 139 (8%) | 22 (8%) |
| Myelodysplastic syndrome | 197 (8%) | 127 (7%) | 20 (7%) |
| Donor status at transplantation | |||
| 1st complete remission/chronic phase | 1262 (48%) | 889 (50%) | 134 (48%) |
| 2nd complete remission/chronic/accelerated phase | 684 (26%) | 445 (25%) | 74 (26%) |
| Relapse/blast phase/refractory anemia excess blasts | 668 (26%) | 460 (26%) | 74 (26%) |
| Transplant characteristics | |||
| Conditioning regimen | |||
| Myeloablative | |||
| Total body irradiation containing | 882 (34%) | 583 (32%) | 87 (31%) |
| Non–irradiation containing | 953 (36%) | 647 (36%) | 109 (39%) |
| Reduced intensity | |||
| Low dose total body irradiation containing | 180 (7%) | 122 (7%) | 15 (5%) |
| Non–irradiation containing | 599 (23%) | 442 (25%) | 71 (25%) |
| GVHD prophylaxis | |||
| Tacrolimus-containing | 2065 (79%) | 1405 (78%) | 215 (76%) |
| Cyclosporine-containing | 549 (21%) | 389 (22%) | 67 (24%) |
| In vivo T-cell depletion | |||
| Yes | 935 (36%) | 680 (38%) | 119 (42%) |
| None | 1679 (64%) | 1114 (62%) | 163 (58%) |
| Graft type | |||
| Bone marrow | 625 (24%) | 458 (26%) | 70 (25%) |
| Peripheral blood | 1989 (76%) | 1336 (74%) | 212 (75%) |
| Follow up, median (range), months | 25 (3-65) | 28 (3-62) | 25 (3-61) |
| . | Donor age, years . | ||
|---|---|---|---|
| 18 to 32 . | 33 to 50 . | >50 . | |
| Number | 2614 | 1794 | 282 |
| Donor characteristics | |||
| Donor-recipient HLA-match | |||
| 8/8 matched | 2114 (81%) | 1326 (74%) | 181 (64%) |
| 7/8 matched | 500 (19%) | 468 (26%) | 101 (36%) |
| Donor-recipient ABO match | |||
| Matched | 874 (33%) | 563 (31%) | 79 (28%) |
| Minor mismatch | 453 (17%) | 374 (21%) | 53 (19%) |
| Major mismatch | 615 (24%) | 442 (25%) | 86 (30%) |
| Not reported | 672 (26%) | 415 (23%) | 64 (23%) |
| Donor sex and parity | |||
| Male | 1789 (68%) | 1218 (68%) | 153 (54%) |
| Female, nulliparous | 645 (25%) | 110 (6%) | 26 (9%) |
| Female, parity, 1 or more | 157 (6%) | 448 (25%) | 102 (36%) |
| Not reported | 23 (<1%) | 18 (1%) | 1 (<1%) |
| Donor-recipient cytomegalovirus serostatus | |||
| Donor and recipient negative | 772 (30%) | 504 (28%) | 57 (20%) |
| Donor negative, recipient positive | 992 (38%) | 580 (32%) | 94 (33%) |
| Donor and recipient positive | 229 (9%) | 229 (13%) | 38 (13%) |
| Donor positive, recipient positive | 598 (23%) | 461 (26%) | 86 (30%) |
| Not reported | 23 (< 1%) | 20 (1%) | 7 (2%) |
| Patient characteristics | |||
| Patient age, years | |||
| <18 | 304 (12%) | 198 (11%) | 22 (8%) |
| 18 to 45 | 938 (36%) | 605 (34%) | 101 (36%) |
| >45 | 1372 (52%) | 991 (55%) | 159 (56%) |
| Performance score | |||
| <90 | 822 (31%) | 589 (33%) | 86 (30%) |
| 90 or 100 | 1702 (65%) | 1124 (63%) | 190 (67%) |
| Not reported | 90 (3%) | 81 (5%) | 6 (2%) |
| Disease | |||
| Acute myeloid leukemia | 1630 (62%) | 1122 (63%) | 174 (62%) |
| Acute lymphoblastic leukemia | 593 (23%) | 406 (23%) | 66 (23%) |
| Chronic myeloid leukemia | 194 (7%) | 139 (8%) | 22 (8%) |
| Myelodysplastic syndrome | 197 (8%) | 127 (7%) | 20 (7%) |
| Donor status at transplantation | |||
| 1st complete remission/chronic phase | 1262 (48%) | 889 (50%) | 134 (48%) |
| 2nd complete remission/chronic/accelerated phase | 684 (26%) | 445 (25%) | 74 (26%) |
| Relapse/blast phase/refractory anemia excess blasts | 668 (26%) | 460 (26%) | 74 (26%) |
| Transplant characteristics | |||
| Conditioning regimen | |||
| Myeloablative | |||
| Total body irradiation containing | 882 (34%) | 583 (32%) | 87 (31%) |
| Non–irradiation containing | 953 (36%) | 647 (36%) | 109 (39%) |
| Reduced intensity | |||
| Low dose total body irradiation containing | 180 (7%) | 122 (7%) | 15 (5%) |
| Non–irradiation containing | 599 (23%) | 442 (25%) | 71 (25%) |
| GVHD prophylaxis | |||
| Tacrolimus-containing | 2065 (79%) | 1405 (78%) | 215 (76%) |
| Cyclosporine-containing | 549 (21%) | 389 (22%) | 67 (24%) |
| In vivo T-cell depletion | |||
| Yes | 935 (36%) | 680 (38%) | 119 (42%) |
| None | 1679 (64%) | 1114 (62%) | 163 (58%) |
| Graft type | |||
| Bone marrow | 625 (24%) | 458 (26%) | 70 (25%) |
| Peripheral blood | 1989 (76%) | 1336 (74%) | 212 (75%) |
| Follow up, median (range), months | 25 (3-65) | 28 (3-62) | 25 (3-61) |